Motexafin gadolinium: a novel radiosensitizer for brain tumors. (Q36842747)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17555388%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

review article

1 reference

title

Motexafin gadolinium: a novel radiosensitizer for brain tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17555388%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17555388%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

Afshin Forouzannia

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17555388%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Gregory M Richards

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17555388%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Deepak Khuntia

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17555388%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

publication date

1 June 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17555388%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anticancer Therapy

31 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17555388%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17555388%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17555388%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

785-794

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17555388%20AND%20SRC:MED&resulttype=core&format=json

The treatment of brain metastases from lung cancer

31 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.785

Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.785

Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.785

A randomized trial of surgery in the treatment of single metastases to the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.785

The mechanism of action of radiosensitization of conventional chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.785

Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.785

Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.785

Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.785

21 January 2018

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.785

Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.785

Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.785

Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.785

Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: Report of RTOG trial 89-05

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.785

RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.785

Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.785

Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.785

Motexafin gadolinium in the treatment of brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.785

Motexafin gadolinium: a novel redox active drug for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.785

Motexafin gadolinium: a possible new radiosensitiser

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.785

Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.785

Effects of texaphyrins on the oxygenation of EMT6 mouse mammary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.785

Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.785

Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.785

Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.785

Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.785

Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.785

Motexafin-gadolinium taken up in vitro by at least 90% of glioblastoma cell nuclei.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.6.785

21 January 2018

Identifiers

DOI

10.1586/14737140.7.6.785

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17555388%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference